We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

High Dose Chemotherapy and Autologous Transplant for Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2007 by Stanford University.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00186641
First Posted: September 16, 2005
Last Update Posted: July 11, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Stanford University
  Purpose
To determine survival outcomes for patients with chemosensitive brest cancer after treatment with high dose chemotherapy

Condition Intervention Phase
Graft vs Host Disease Procedure: high dose chemo and auto hematopoietic cell transplant Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: High Dose Chemotherapy and Peripheral Blood Progenitor Cell Rescue for Patients With Breast Cancer

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Survival

Estimated Study Completion Date: March 2005
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stage II, III or IV breast cancer
  • chemosensitive
  • adequate organ function

Exclusion Criteria:

  • prior transplant,
  • life threatening disease
  • brain metastases
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00186641


Locations
United States, California
Stanford University Cancer Center
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Ginna Laport, MD Stanford University
  More Information

ClinicalTrials.gov Identifier: NCT00186641     History of Changes
Other Study ID Numbers: BMT42
First Submitted: September 14, 2005
First Posted: September 16, 2005
Last Update Posted: July 11, 2007
Last Verified: July 2007

Keywords provided by Stanford University:
chronic Graft vs Host Disease

Additional relevant MeSH terms:
Graft vs Host Disease
Immune System Diseases